CytoReason Cements Proof-of-Concept with Machine-Learning-Facilitated Biomarker Breakthrough in Anti-TNFα Treatment Failure ...
April 16 2018 - 12:20PM
Business Wire
CytoReason’s proprietary technology demonstrates ability to
reconstruct hidden cellular signals, extrapolate one tissue to
another and identify immune system relationships capable of
revealing new biomarkers and potential new treatment targets for
immune-related drugs.
New data published in the prestigious BMJ journal, Gut, outlines
the role of a new technological platform approach that has revealed
a new blood-based biomarker that is 94% accurate in pretreatment
identification of anti-TNFα non-responders in inflammatory bowel
disease (IBD), accounting for approximately 30% of patients,
confirming validity of the approach.
The application of this platform led to the identification of
the TREM1-CCR2-CCL7 axis (which manages the movement of
inflammatory monocytes) and plasma cell abundance as accurate
pretreatment markers of anti-TNFα response in inflammatory bowel
disease (IBD). The study demonstrated TREM-1 expression in
peripheral blood to be an accessible and accurate predictor of
non-response. The findings demonstrate the platform’s ability to
reconstruct previously lost cellular information and isolate an
easier to access blood-based biomarker.
The data showcases CytoReason’s ability to provide unique
immune-system insights and interpretation that generate new
directions for enhanced target identification, improved indication
assessment, more effective clinical development and advanced
real-world evidence strategies that can be embedded in the
development process.
Identifying blood-based biomarkers for IBD has traditionally
been extremely difficult to do. The site of disease is the gut,
which is a complex tissue, composed of multiple cell types, whose
relation to blood in unclear.
“The overall results were impressive in their clarity and
output” said Professor Shai Shen-Orr, PhD., Chief Scientist at
CytoReason and Director of the Systems Immunology & Precision
Medicine Lab in the Faculty of Medicine at The Technion, Israel
Institute of Technology. “We demonstrated our ability to recreate
and separate out cellular contributions from bulk tissue
measurements, discovering a pretreatment upregulated pathway
uniquely in anti-TNFα non-responders. Furthermore, we established a
clear biomarker relationship between biopsy and blood, which we
were able to validate with high accuracy.”
"With more than a decade of research behind our unique platform,
I am delighted to further demonstrate our ability to uncover
critical immunological insights, vital to R&D teams in the
discovery, validation and development of targets and the mitigation
of clinical development risks", remarked David Harel, President and
Chairman of CytoReason. “This is exciting news for drug developers,
who can use our unique approach to exquisitely define research
directions. Ultimately, this is great news for the millions of
patients who rely on the discovery, development and availability of
innovative and effective new therapeutic options.”
About CytoReasonBased on more than 10 years of research,
CytoReason’s technology uses a proprietary data and machine
learning model to reconstruct cellular information from bulk
tissue, to train an immune-specific NLP engine, and to integrate
multi-omics data. The company’s platform organizes and standardizes
collaborators’ data (gene, protein, cell, and microbiome) and
integrates it into CytoReason’s proprietary disease model to
generate mechanistic understanding of the immune system, leading to
novel insights.
CytoReason’s technology has yielded 2 pending patents,
9 commercial and scientific collaborations and 14
peer reviewed publications. Fully applicable to cancer
immunotherapy, autoimmune, neurodegenerative and infectious disease
research, CytoReason is at the cutting edge of society’s boldest
attempts to improve health outcomes through better understanding of
the immune system.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180416006063/en/
Company Media:Michelle Chiera, +972 52-600-0446 (Cell)Blonde 2.0
for CytoReasonmichelle@blonde20.com